Publications by authors named "Juan Carlos Lopez-Azor Garcia"
Article Synopsis
- Heart transplant recipients (HTr) are at greater risk for severe COVID-19, and a study analyzed their prognosis over the pandemic from February 2020 to October 2022.* -
- Among 308 HTr studied, 39.2% were infected; those with pneumonia had significantly worse outcomes, with higher hospitalization and death rates compared to less severe cases.* -
- Improvements in prognosis were noted over time, with reduced pneumonia (from 62% to 19%) and mortality (from 23% to 4%), attributed to factors like vaccination and early remdesivir treatment.*
Antibodies directed against donor-specific human leukocyte antigens (HLAs) can be detected de novo after heart transplantation and play a key role in long-term survival. De novo donor-specific antibodies (dnDSAs) have been associated with cardiac allograft vasculopathy, antibody-mediated rejection, and mortality. Advances in detection methods and international guideline recommendations have encouraged the adoption of screening protocols among heart transplant units.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to assess the prevalence and prognostic significance of donor-transmitted coronary artery disease (TCAD) in heart transplant patients across 11 Spanish hospitals from 2008 to 2018.
- Out of 1,918 heart transplant patients, 937 had coronary angiography (c-angio) within the first three months, revealing that 18.3% had TCAD, with 6.9% having significant TCAD (s-TCAD) and 11.4% having nonsignificant TCAD (ns-TCAD).
- The study found that while s-TCAD did not significantly impact overall survival, it was linked to a higher risk of cardiovascular death and major adverse cardiovascular events, indicating a